Cancer Research UK
www.cancerresearchuk.org
Latest From Cancer Research UK
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.
UK Receives £1bn Confidence Boost From Industry Investment In Life Sciences Sector
The international biopharma industry is backing the UK life sciences sector, with UCB spearheading the charge with a £1bn commitment to R&D in the nation still in a state of flux regarding its exit from the European Union in 2019.
UK Charity Aims To Knock Years Off Lung Cancer Vaccine Development
Having linked up with Asterias, Nigel Blackburn, Cancer Research UK’s director of drug development, tells Scrip that a pact covering the US firm's allogeneic cancer vaccine made from dendritic cells is typical of a project "that without our help could either stall or languish."
Tech Transfer Roundup: United Neuroscience Unveils Pair Of Collaborations In CTE, Alzheimer’s
Irish biotech focused on Endobody vaccine candidates partners with Boston U. in CTE and U. of Texas in Alzheimer’s. Lupus Research Alliance affiliate will help Bristol conduct a Phase II trial of Tyk2 inhibitor in lupus.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice